Charing Cross Symposium 2018: Real World DCB Registry BIOLUX P-III Shows Excellent 12-Month Results in the Full Cohort and BTK Subgroup
BIOTRONIK announced the latest results of three lower limb clinical trials – BIOLUX P-III, BIOFLEX PEACE and BIOLUX 4EVER
1Brodmann M. Certificate of Merit Winner CX 2017 - Real-world experience with a paclitaxel-coated balloon for the treatment of atherosclerotic infrainguinal arteries. Twelve-month results of the BIOLUX P-III all-comers registry for the full cohort. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02276313
2Not currently available in the United States.
3Tepe G. BIOLUX P-III, Passeo-18 Lux registry: 12-month Results in BTK. Presented at: Charing Cross 2018. April 24, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02276313
4Lichtenberg M, BIOFLEX PEACE all-comer registry. Prospective multicenter registry for the treatment of stenosis and occlusion of the superficial femoral artery using the 4F Pulsar-18 stent. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom.
5Deloose K. BIOLUX 4EVER physician-initiated, prospective, multicenter, controlled trial investigating the efficacy of endovascular treatment of femoropopliteal arterial stenotic disease with Passeo-18 Lux drug-coated balloon and Pulsar-18 stent. Presented at: Charing Cross 2018; April 25, 2018; London, United Kingdom. ClinicalTrials.gov: NCT02211664
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.